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Abstract
Sonic hedgehog (Shh) signaling plays a key role in regulating normal development. The negative 
feedback mechanism mediated by the transcriptional factor, Gli3, acts to finely tune Shh signaling, 
providing tight control of normal developmental processes. Hyperactivation of Shh signaling often 
leads to many human malignancies, including basal cell carcinoma and medulloblastoma (MB). 
However, how tumor cells sustain the aberrant activation of Shh signaling is still not completely 
understood. We recently revealed that during MB formation, tumor cells express Nestin, a type VI 
intermediate filament protein, which maintains uncontrolled Shh signaling by abolishing negative 
feedback by Gli3. Therefore, Nestin expression is a necessary step for MB formation. These 
findings highlight the novel function of Nestin in regulating Shh signaling, as well as the 
important role of a disrupted negative feedback mechanism in MB tumorigenesis. Further, 
restoration of the intrinsic negative feedback by repressing Nestin expression represents a 
promising approach to treat MB as well as other Shh signaling associated malignancies.
Graphical abstract. A model for medulloblastoma tumorigenesis
Nestin expression is indispensable for Shh type medulloblastoma tumorigenesis. To achieve this, 
Nestin augments Shh signaling in medulloblastoma cells by abolishing Gli3-mediated negative 
feedback mechanism.
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1. Introduction
Proper development of multi-cellular organisms relies on the coordination of a diverse array 
of signal transduction pathways. Most signaling events are required to stay homeostatically 
active under precise regulation by activating as well as repressing signals. In many cases, 
negative feedback mechanisms act to dampen signal transduction, preventing aberrant 
pathway activation.
Negative feedback regulation is particularly important in the Shh signaling pathway. Shh 
signaling plays a fundamental role during normal vertebrate development by regulating 
tissue patterning, cell proliferation and differentiation, as well as fate determination. Shh 
ligand is a secreted protein, which acts by activating a protein complex, consisting of 
transmembrane receptors Patched 1 (Ptch1) and Smoothened (Smo). In the absence of Shh 
ligand, its receptor Ptch1 inhibits pathway effector Smo, preventing the activation of Shh 
pathway. When Shh ligand is present, its binding to Ptch1 results in the subsequent 
activation of Smo, which in turn leads to transcription of Gli zinc-finger transcriptional 
factors and pathway activation [1]. In mammalian cells, there are three Gli protein members 
- Gli1, Gli2 and Gli3, which are normally tethered to the cytoskeleton. Gli proteins are 
essential effectors of Shh signaling which determine the pathway outcome. The functions of 
Gli proteins are regulated by proteolytic processing into balanced full-length transcriptional 
activators or truncated repressor forms. Gli1 and Gli2 are generally considered to be 
activators of Shh signaling, while Gli3 predominantlyimparts a repressive function. Full-
length Gli3 is mostly processed into its repressor form, which acts as a major negative 
regulator of Shh signaling transduction [2, 3]. After proteolytic processing, the truncated 
Gli3 translocates into cell nuclei to repress the activation of Shh pathway (Figure 1). The 
negative feedback loop mediated by Gli3 plays an important role in ensuring the activation 
of Shh pathway at physiologic levels.
In the cerebellum, Shh ligand is released from Purkinje neurons and stimulates the 
proliferation of granule neuron precursors (GNPs) in the external granule layer (EGL). 
During the first 2-3 postnatal weeks in mice, GNPs exit the cell cycle, differentiate and 
migrate inward to form the internal granule layer. In parallel, Shh signaling is gradually 
down-regulated in GNPs, even in the Shh-enriched environment [4, 5]. Aberrant activation 
of Shh pathway in GNPs caused by loss of Ptch1, drives ectopic proliferation of GNPs. After 
prolonged proliferation, Shh signaling diminishes in the majority of Ptch1-deficient GNPs. 
Only a rare population of cells sustains activation of the Shh pathway and ultimately results 
in the formation of MB [6]. The discrepancy between the normal developmental self-
restricted activation of signaling in GNPs and the abnormal proliferation with aberrant 
pathway activation implies the importance of negative regulation of the Shh pathway. This 
observation suggests that the disruption of the negative regulation on Shh signaling is critical 
for MB tumorigenesis.
We have recently found that during MB formation, tumor cells gradually express Nestin, a 
type VI intermediate filament protein. Nestin expression plays a critical role in MB 
tumorigenesis by sustaining aberrant Shh signaling in MB cells. To achieve this, Nestin 
impairs the inhibitory regulation of Gli3, driving MB initiation and progression [7]. Our 
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studies highlight the novel function of Nestin in regulating Shh signaling and the importance 
of disruption in the negative feedback regulation in the tumorigenesis of MB. In this review, 
we summarize the expression and functions of Nestin in regulating Shh signal transduction 
and the negative feedback mechanism in tumorigenesis and the therapeutic implications of 
the negative feedback.
2. General knowledge of Nestin and its expression in tumors
Nestin, first identified in the neural stem cell (NSC) in 1985, is widely considered a putative 
marker for stem cells [8, 9]. The human Nestin gene encodes a large protein consisting of 
1621 amino acids. Structural organization of the Nestin gene is evolutionarily conserved 
between human, rat and mouse, indicative of its functional significance [10]. Nestin 
expression is predominantly regulated by enhancer regions in the first and second introns of 
the Nestin gene [11, 12]. A 714 bp conserved 3′ portion of the second intron is sufficient to 
control Nestin expression in progenitors in the central nervous system. An enhancer region 
of the Nestin gene is found in the second intron and is divided into two separate domains 
[13]: the 3′ region required to induce Nestin expression in pan-CNS progenitors and the 
other controlling expression in the midbrain. The putative binding sites located in the second 
intron of the Nestin gene include Retinoic Acid Receptor (RAR), Retinoid X Receptor 
(RXR), and Thyroid Hormone Receptor (TR) [14, 15]. In human umbilical vein endothelial 
cells, Nestin expression was found to be regulated by an element in the first intron [16].
Similar to other intermediate filaments, such as cytokeratin and vimentin, Nestin consists of 
an α-helical rod domain, flanked by N-terminal ‘head’ and C-terminal ‘tail’ domains. The 
highly conserved rod domain of the Nestin protein contains several α-helical coils that 
assemble in antiparallel fashion, resulting in filament formation. The alignment of stable 
dimers and cohesive forces between adjacent dimers determines the properties of high 
stability and plasticity in the formed Nestin [17, 18]. Unlike the majority of other 
intermediate filaments, Nestin was characterized as having an unusually long C-terminal 
domain and a relatively short N-terminal domain, which define its self-assembly 
characteristics [17]. The C-terminal domain gives Nestin a remarkable binding capacity to a 
wide range of proteins and serves as a platform for cell signal integrations. The short N-
terminal domain limits the self-polymerization capability in Nestin, leaving its filament 
formation to be entirely dependent on interactions with other intermediate filament proteins. 
It is well established that Nestin often forms complexes with vimentin and α-internexin, 
allowing formation of stable cytoskeletal intermediate filament networks which maintain the 
structural integrity of the cells [19-21].
Nestin expression is very dynamic and tightly regulated, both spatially and temporally. 
Although Nestin is commonly utilized as an NSC marker, it is expressed by a variety of 
progenitor cells, including skin and hair follicle, muscular, renal, hepatic, endothelial, 
mesenchymal, hematopoetic and neuronal progenitors [22-31]. In general, the expression of 
Nestin is primarily correlated with the proliferative stage of such progenitors. As cells exit 
the cell cycle and undergo terminal differentiation, Nestin expression gradually decreases 
and is replaced by tissue-specific intermediate filaments, such as glial fibrillary acidic 
protein in astrocytes, α-internexin and neurofilament in neurons, and desmin in myocytes 
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[32, 33]. Nestin expression is normally down-regulated in mature tissues, but its expression 
can be driven by conditions resembling developmental processes, such as tissue 
regeneration, revascularization and wound healing. For example, Nestin expression was 
observed in regenerating muscle tissue following injury or necrosis, as well as in reactive 
astrocytes during post-injury glial scar formation [34, 35]. Nestin expression has also been 
observed in tissues with pathologic conditions, i.e. in the tooth during carious lesion 
formation or in brain tissue after traumatic injury and ischemia [36].
Nestin expression has also been reported in various human neoplasms. Nestin is highly 
expressed in most tumors that originate from undifferentiated precursors and immature 
progenitors, such as medulloblastoma, neuroblastoma and retinoblastoma [37]. Presence of 
Nestin has also been confirmed in ductal breast carcinoma and pancreatic ductal 
adenocarcinoma [38]. In addition to solid tumors, expression of Nestin protein has been 
found in tumor cells from acute myeloid leukemia and acute lymphoblastic leukemia [39]. In 
addition, Nestin is widely utilized to label “cancer stem cell” populations in variety of 
malignancies, including brain tumors, sarcomas, ovarian and prostate carcinoma, lung, 
breast and pancreatic cancers [38]. Nestin expression is not only present in tumor cells, but 
also in tumor stroma, particularly vascular endothelial cells. It has been reported that Nestin 
is involved in the vasculogenesis in tumor tissue [40]. Overall, Nestin expression is 
associated with malignancy and is indicative of a poor prognosis. In some tumors, including 
malignant melanoma, schwannomas and gastrointestinal tract tumors, Nestin expression is 
utilized as a negative predictive marker[41]. Nestin tends to be found in advanced stage 
tumors. For example, stronger Nestin expression was found in glioblastoma multiforme 
compared to expression in lower grade gliomas [42]. Although Nestin expression has a 
strong correlation with malignancy, invasiveness and decreased survival, the functional role 
of Nestin in the tumorigenesis remains under investigation.
3. Functions of Nestin in Hedgehog signaling and medulloblastoma
MB normally arises on the surface of the cerebellum, but could metastasize to the other parts 
of the central nervous system. Despite the aggressive tumor treatment including surgical 
resection, chemotherapy and radiotherapy, 30% of patients with MB still succumb to this 
disease. Patients who survive MB often suffer with severe long-term effects resulting from 
treatment, including cognitive deficits and increased incidence of secondary tumors [43, 44]. 
Therefore, improved approaches to treating MB are urgently needed.
Human MB comprises at least four subgroups based on their distinct genetic/epigenetic 
profiles: Wnt, Sonic Hedgehog (Shh), Group 3, and Group 4 [45, 46]. The Shh subgroup 
accounts for about 30% of MB cases, which is caused by aberrant activation of the Shh 
signaling pathway. We have previously demonstrated that genetic deletion of Ptch1 in 
cerebellar GNPs leads to MB formation in mice. This indicates that cerebellar GNPs 
represent the cell of origin for MB. However, the majority of Ptch1-deficient GNPs 
ultimately differentiate after prolonged proliferation. Only a small proportion of GNPs in the 
hyperplastic lesions finally develops into MB, suggesting that loss of Ptch1 alone is not 
sufficient for maintenance of constitutive Shh signaling transduction [6].
Gordon et al. Page 4
Biochem Pharmacol. Author manuscript; available in PMC 2018 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our recent studies revealed that cerebellar GNPs gradually express Nestin after Ptch1 
deletion. Loss of Ptch1 causes a transient increase in Shh signaling in GNPs. However, in 
the absence of Nestin, Shh signaling is eventually dampened by the repressor activity of Gli3 
and cells undergo differentiation [6]. In the presence of high levels of Nestin, Gli3 is 
sequestered and Ptch1-deficient GNPs maintain high levels of Shh signaling and go on to 
form tumors. We further demonstrated that the C-terminal domain of Nestin can directly 
bind to Gli3 protein. Physical interaction with Nestin compromises Gli3 phosphorylation 
and impairs its proteolytic processing. In addition, Nestin tethers Gli3 in the cytoplasm and 
prohibits its nuclear translocation, thereby blocking the inhibitory effects of Gli3 on Shh 
signaling [7]. These findings shed light on the molecular mechanisms by which Shh 
signaling drives MB tumorigenesis. Our data demonstrate for the first time that Nestin 
functions to maintain and enhance Hh pathway activation leading to malignancy.
4. Negative feedback loops in tumorigenesis and drug resistance
Negative feedback loops are biological mechanisms that normally operate to lessen various 
types of signaling and thereby precisely tune the signaling outcome. During normal 
development, various signaling pathways stimulate tissue cell proliferation in order to 
produce the proper number of cells. The negative feedback loop in each pathway acts to 
attenuate these proliferative signals. Defects in these critical feedback mechanisms can result 
in uncontrolled proliferative signaling that eventually lead to the tumor formation.
After Hh pathway activation, Gli3 primarily functions to suppress further signal 
transduction. MB cells express Nestin, allowing them to evade the negative regulation of 
Gli3 on Shh signaling. This results in uncontrolled activation of the Shh pathway and 
sustained MB progression. The process of tumor formation is often likened to a car speeding 
out of control. If the gas pedal is stuck, a functioning brake can still bring the car to a full 
stop. If the brake is disconnected at the same time the gas pedal is stuck, the car will 
continue uncontrolled. In a sense, the same thing happens during MB formation. Analogous 
to pushing the gas pedal, activation of the Hh pathway by Ptch1 deletion drives the 
proliferation of cerebellar GNPs. However, the brake of Shh signaling, Gli3 acts to repress 
further pathway activation, so that the majority of GNPs eventually stops dividing and 
differentiates. Only a rare population of Ptch1 deficient GNPs expresses Nestin, abolishing 
the functions of Gli3 and thereby the negative feedback mechanism on Shh signaling. As a 
result, tumor is finally developed. Both Nestin expression (disconnected brake) and loss of 
Ptch1 (stuck gas pedal) are indispensable for MB tumorigenesis (lost control of car) 
(Graphical abstract). Our findings highlight the importance of disruption of these negative 
feedback mechanisms in the process of tumorigenesis.
Disruption of negative feedback loops has been also observed in other signaling pathway 
associated tumorigenesis. For example, Ras GTPase serves as intrinsic negative feedback to 
ensure transient activation of Ras signaling [47]. The oncogenic effects of Ras do not result 
from a hyperactivation of its signaling powers, instead mutations in the Ras gene 
compromise the inhibitory capability of Ras GTPase [48]. In addition, PTEN phosphatase 
counteracts PI3K by degrading its product, phosphatidylinositol (3,4,5) triphosphate (PIP3). 
Loss-of-function mutations of PTEN induce tumorigenesis of many human malignancies 
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through activation of PI3K pathway. Such compromised negative feedback loops in 
proliferative signaling pathways are widely present among human cancer cells and serve as 
an important means by which these cells achieve proliferative advantage [48].
Negative feedback is also involved in drug resistance during tumor treatment. In the 
RAF/MEK/ERK signaling cascade, the negative feedback from ERK to RAF effectively 
attenuates the pathway activity. MEK inhibitors weaken the feedback signal and upregulate 
RAF compensating for the initial loss of ERK activity [49]. Thus, tumor cells often exhibit 
resistance to sole treatment with MEK inhibitors. Thus, a combination of MEK and RAF 
inhibitors is currently considered a standard strategy for melanoma treatment. Negative 
feedback has also been found to underlie resistance against drugs targeting the PI3K/Akt/
mTOR pathway, which is hyperactivated in many types of tumors. In normal cells, 
stimulation of IGF activates insulin receptor substrates (IRS1/2) that trigger the downstream 
PI3K/Akt/mTOR cascade. mTOR represses the interaction between IRS 1/2 and IGF 
receptor, generating a negative feedback loop from mTOR to IRS 1/2. mTOR inhibitors 
often lead to relief of the feedback, which causes increased IRS signaling and induction of 
the kinases upstream of mTOR, PI3K and Akt [50]. This is commonly believed to be the 
mechanism of tumor cell resistance to mTOR inhibitors.
5. Tumor treatment by restoring the negative feedback
Mutations and dysregulation of the Shh pathway often lead to tumorigenesis and accelerated 
tumor growth in many tissue types. Basal cell carcinoma and MB are two well-recognized 
tumors with mutations in components of the Shh pathway. Inappropriate activation of the 
Shh pathway has been implicated in the development of several other types of cancer 
including lung, prostate, breast and pancreas [51, 52]. In addition, Shh signaling can also 
drive tumor initiation and progression through stimulation of cancer stem cells or alteration 
of the surrounding stroma [52]. The Shh signaling pathway has been recognized to be one of 
the most important therapeutic targets in tumor treatment.
As a critical effector of Shh signaling, Smo has been the primary target for development of 
Hh pathway inhibitors. Smo inhibition prevents the downstream activation of Gli 
transcription factors, leading to suppression of those genes associated with cancer growth 
and progression [53]. Vismodegib and Sonidegib are approved by the FDA to treat advanced 
or metastatic basal cell carcinoma. Several other Smo antagonists, including XL139, 
Glasdegib, Taladegib and Saridegib are currently utilized as a monotherapy or in 
combination in clinical trials to treat a wide array of cancers, including MB, small cell lung 
cancer, metastatic pancreatic cancer, metastatic prostate cancer, recurrent glioblastoma and 
hematological malignancies [54]. Although initial findings suggest that while available Smo 
antagonists exhibit initial therapeutic efficacy, there is a rapid emergence of drug resistance 
[55, 56]. In many cases, resistance arises as a consequence of mutations in Smo that prevent 
binding of the antagonists or genetic events that activate downstream components of the Shh 
pathway [57, 58]. Additionally, Smo antagonists globally repress Shh signaling, even in 
normal cells. In particular, MB is a brain tumor that mainly affects children and Shh 
signaling is necessary for normal development of many tissues in patients. Thus, Smo 
antagonists can cause severe developmental side effects, such as bone defects and endocrine 
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disorders [59]. Smo antagonists are contraindicated during pregnancy as they are 
teratogenic, embryotoxic and fetotoxic. Other adverse reactions include alopecia, muscle 
spasms, weight loss, fatigue, GI disturbance and arthralgias. Therefore, novel inhibitors with 
improved efficacy and fewer toxicities are still required to treat Shh pathway associated 
malignancies.
In our studies, Nestin expression represents a necessary step for MB tumorigenesis and it 
promotes MB growth by augmenting Shh signaling by abolishing Gli3 negative feedback. 
Therefore, targeting Nestin in MB cells could restore the inhibitory functions of Gli3 and 
repress hyperactivation of Shh pathway. We have shown that inhibition of Nestin expression 
effectively blocks MB formation in mice, indicating that Nestin expression represents a 
promising therapeutic target to treating MB. Further, disruption of the negative feedback of 
Shh signaling is only present in MB cells and the Gli3 inhibitory mechanism is intact in 
normal cells. Indeed, Nestin expression is present only in MB cells, but not normal GNPs. 
Thus, recovery of negative feedback by repressing Nestin expression could cause much less 
on-target toxicity, compared to Smo antagonists. Since Nestin regulates Gli3 activity 
downstream of Smo, inhibition of Nestin expression may be effective for treatment of drug-
resistant MB as well as other Shh pathway associated malignancies.
The functions of Nestin in tumorigenesis were not recognized until recently. As an 
intracellular cytoskeletal protein, Nestin itself may not represent an ideal pharmaceutical 
target. Therefore, no inhibitors antagonizing the functions of Nestin are currently available 
in preclinical studies and/or in clinical trial. On the other hand, Nestin expression is not 
limited to tumor cells, but also found in normal stem cells, especially NSCs. It was 
previously reported that Nestin was required for the self-renewal of NSCs [33]. Direct 
inhibition of Nestin functions could cause toxicities in NSCs, precluding clinical utilization 
of Nestin itself as a therapeutic target in MB treatment. However, mechanisms underlying 
Nestin induction in tumor cells may represent an attractive target for MB treatment. Our 
previously studies suggest that Nestin expression in MB cells relies on the unique tumor 
microenvironment [7]. Ongoing studies in our laboratory are to address the cellular and 
molecular basis for Nestin expression in tumor cells during MB development. Elucidation of 
mechanisms for Nestin expression in tumor cells and normal NSCs could help to develop a 
promising approach to treat MB by targeting Nestin induction.
6. Conclusion
Though Nestin is widely used as a marker for NSCs, recent studies have revealed that Nestin 
participates in the regulation of many signaling pathways [60] [61]. The wide and dynamic 
expression pattern of Nestin encourages further investigation of the diverse functions of 
Nestin during normal development and pathological processes. It is becoming clearer that 
Nestin and other cytoskeletal proteins play important roles in a number of signaling events 
by direct contribution in signaling transduction or provision of ample surface for protein-
protein interaction. Therefore, cytoskeletal proteins could potentially be utilized as targets to 
manipulate cell signaling activity to resolve a variety of diseases.
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Our previous studies revealed that Nestin promoted the tumorigenesis of Shh pathway-
associated MB by inhibiting Gli3. However, Nestin expression was also detected in non-Shh 
type of human MB including Wnt type, group 3 and group 4, where Shh pathway is not 
involved in the tumor initiation and progression [7]. Nestin may modulates other signaling 
pathways that are essential for tumorigenesis of non-Shh type MB, which are warranted for 
future studies.
Negative feedback mechanisms are crucial in dynamic regulation of developmental 
signaling. Recent studies highlight the important role of disrupted negative feedback in 
tumorigenesis. These findings significantly further our understanding of the molecular basis 
underlying tumor initiation and progression and provide novel targets to explore 
therapeutically for tumor treatment. Because negative feedback dramatically alters drug 
sensitivity and dose-responsiveness, for tumor treatment to be successful, it is critical to 
surpass drug resistance by careful understanding of feedback loops of signaling pathways.
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Figure 1. Nestin augments Shh signal transduction by inhibition its repressor, Gli3
Shh ligand interacts with its antagonizing receptor Ptch1, which activates the effector 
protein, Smo, leading to nuclear translocation of the Gli family of transcriptional factors: 
Gli1, Gli2 and Gli3. While Gli1 and Gli2 act primarily as transcriptional activators, Gli3 
blocks subsequent transcription of Shh pathway target genes (Gli1, Ptch1, etc.), acting as an 
essential negative regulator of Shh signaling transduction. Recent work from our laboratory 
has demonstrated that Nestin mediates Shh pathway associated tumorigenesis by abolishing 
the inhibitory functions of Gli3 on Shh signaling [7].
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